1. A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea
- Author
-
Miaomiao Ji, Qiuju Li, Ming Yuan, Yufei Huang, Jing Li, Guoyun Wang, and Xue Jiao
- Subjects
medicine.medical_specialty ,medicine.drug_class ,Anemia ,Visual analogue scale ,Endocrinology, Diabetes and Metabolism ,Uterus ,Gastroenterology ,Cohort Studies ,Gonadotropin-Releasing Hormone ,chemistry.chemical_compound ,Endocrinology ,Dysmenorrhea ,Gonadotropin-releasing hormone agonist ,Internal medicine ,Statistical significance ,Humans ,Nandrolone ,Medicine ,Adenomyosis ,business.industry ,Goserelin Acetate ,Obstetrics and Gynecology ,medicine.disease ,medicine.anatomical_structure ,Dienogest ,chemistry ,Goserelin ,Female ,business - Abstract
PURPOSE To study the efficacy and safety of the dienogest and the gonadotropin-releasing hormone agonist (GnRH-a) in symptomatic females with uterine adenomyosis. METHODS A total of 127 patients with adenomyosis with a chief complaint of dysmenorrhea were recruited. The first group received 2 mg of dienogest (DNG) daily, whereas the second group received goserelin acetate (GS) (3.6 mg/4 weeks) for 12 weeks. Outpatient follow-up was undertaken after 12 weeks. RESULTS Among 127 women, 56/63 (88.9%) patients completed the treatment in the DNG group, whereas 62/64 (96.9%) patients completed the treatment in the GS group. A significant decrease in dysmenorrhea symptoms as measured by the visual analog scale (VAS) and Carcinoma antigen125 (CA125) after 12 weeks of treatment was observed in both groups (p
- Published
- 2021